Broughton Director of Product Safety and Compliance, Yvonne Wilding, discusses a leading-edge software tool designed and in use at Broughton to assist with toxicological screening and risk...
We’ve officially left the EU, but what does Brexit mean for ENDS Manufacturers?
May 13, 2021 | Published by Yvonne Wilding
Broughton Director of Product Safety and Compliance, Yvonne Wilding, discusses implications of Brexit on the international ENDS market.UK leaving the EU
The UK recently left the EU – so what does that mean for British-based and overseas Electronic Nicotine Delivery Systems (ENDS) manufacturers who have a share of the UK ENDS market?
So far, there have been no significant changes to requirements for product development or sale of ENDS and tobacco products. For medical device purposes, however, Great Britain (GB) now acts independently, separate from Northern Ireland who continue to follow European guidance.
A minor change that has been implemented by the Tobacco Products and Nicotine Inhaling Products (Amendment) (EU Exit) Regulations 2020 is the introduction of a new portal. Manufacturers will now need to notify the Great Britain Domestic System to sell e-cigarettes in GB.
To enter the Northern Ireland market, manufacturers will still need to notify the EU Common Entry Gate system.
In terms of medical device legislation, new EU regulations are due to take effect in May but as GB has left the EU, these changes will not be applicable, and GB will continue to work under the existing medical device directive.
The British government has already announced a new certification scheme that will be introduced, called the UK Conformance Acceptance (CA) mark. Manufacturers will need the UK CA mark to sell ENDS products in the UK. The UKCA pathway was introduced in January 2021 but the EU CE mark will be acceptable for products marketing in UK for some time.
Additionally, the medical device and product approval bill which is currently going through parliament will impact the development of consumer and medical products. However, as it has not yet been passed, this will have no significant impact on manufacturers in the near future.
In terms of product development requirements, it is unlikely that the Medicines and Healthcare products Regulatory Agency (MHRA) will stray from current International Conference for Harmonisation (ICH) guidelines in the short term. However, laws around the sale and marketing of cigarette replacement products may become stricter once reviewed.
Both the Tobacco and Related Products Regulations 2016 and Tobacco Products and Nicotine Inhaling Products (Amendment) (EU Exit) Regulations 2020 are also due for review in May this year, however, it is possible that the update will be postponed until 2022 due to the pandemic.
Potential Opportunities for ENDS
Following Brexit, there are several opportunities apparent for ENDS manufacturers based in the UK or selling to the UK market:
- Great Britain can now form legislation that is appropriate for the protection of the public health of Britain
- The British Government is likely to be able to pass new laws quicker than EU’s multiple members who have to gain agreement across multiple member states
- Public Health England’s dedication to reducing cigarette consumption is likely to favour safer alternatives
- British Government’s desire to promote the UK as a great place to do scientific research and development
Advice for ENDS Manufacturers
For medical products, manufacturers should make efforts to engage with MHRA during the product development stage and maintain regular dialogue to understand safety and quality requirements.
Manufacturers should also seek to engage a notified body for developing the ENDS device (drug-device combination product). There is a shortage of appropriate notified bodies so if you can recruit one and liaise regularly to align the product components (liquid and device), this will be advantageous for conformance assessments.
Broughton can offer expert guidance to manufacturers during product development and help simplify the regulatory application process. Contact us to arrange a meeting to discuss how we can help you achieve MHRA-compliant products.
Can we help you?
Broughton have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; advancing a smoke-free future.
Book a meeting with us today to discuss your requirements.